Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798561 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate ASN008 Topical Gel (TG)
A Phase 1 study of Dermatitis, Atopic and Pruritus, sponsored by Asana BioSciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 5
- Study locations
NCT03798561 is a Phase 1 study of Dermatitis, Atopic and Pruritus that has completed, run by Asana BioSciences. The registered enrollment target is 24 participants, below the 396-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03798561, a Phase 1 study of Dermatitis, Atopic and Pruritus, has completed, sponsored by Asana BioSciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an ascending dose escalation study to test the safety, tolerability and preliminary efficacy of ASN008 TG in first-in-human subjects
Conditions Studied
Interventions
- DRUG ASN008 TG
- DRUG Placebo TG
Study Locations (5)
New York
- Certified Research Associates - Cortland
North Carolina
- Dermatology Consulting Services, PLLC - High Point
Texas
- Progressive Clinical Research - San Antonio
Wisconsin
- Spaulding Research Clinic, Inc - West Bend
Quebec
- Innovaderm Recherches Inc - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2020-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03798561
The ClinicalTrials.gov registry entry for NCT03798561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 396-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (94% lower). The listed sponsor is Asana BioSciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which ASN008 TG is the first listed.
NCT03798561 reports 5 study locations spanning 5 distinct geographic areas - top geographies include New York, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT03798561 about?
NCT03798561 is a clinical study titled "Study to Evaluate ASN008 Topical Gel (TG)". This is an ascending dose escalation study to test the safety, tolerability and preliminary efficacy of ASN008 TG in first-in-human subjects
What is the current status of trial NCT03798561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-01-14. Estimated completion is 2020-03-20.
What conditions does trial NCT03798561 study?
This clinical trial studies the following conditions: Dermatitis, Atopic, Pruritus, Dermatitis Eczema.
What interventions are being tested in trial NCT03798561?
The interventions under investigation include: ASN008 TG (DRUG), Placebo TG (DRUG).
Who is sponsoring clinical trial NCT03798561?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03798561 being conducted?
This trial has 5 study locations across New York, North Carolina, Texas, Wisconsin, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
COMPLETED · Phase 1
-
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
COMPLETED · Phase 1
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.